Allard Background. Hepatic insulin resistance (HIR) is believed to be a primary pathogenic mechanism for the development of NASH. Recently, non invasive measures

of HIR using an oral glucose tolerance test have been suggested as diagnostic markers of NAFLD. Methods. A prospective study was performed in 33 (14M, 19F) well characterized non-diabetic patients with NASH and 23 healthy, weight matched controls (8M, 15F) to assess the relationship between indices of insulin resistance and histological severity of NASH. All subjects had a 2 hour oral glucose tolerance test. The homeostasis model assessment (HOMA) index was calculated as fasting insulin xfasting glucose/22.5. HIR index was calculated in 2 ways: AUC0-30min glucose × AUC0-30min insulin and the formula: find more -0.091 + (log insulin AUC0-120min × 0.400) + (log fat mass % × 0.346) -(log HDL Cholesterol × 0.408) + (log BMI × 0.435). AUC90-120 glucose and insulin were also calculated. AZD9291 The trapezoidal method was used to calculate glucose and insulin AUC

during an OGTT. Chi square test, analysis of variance and area under the curve were determined for comparing NASH with controls and for histological severity of NASH. Results. Patients with NASH had significantly higher (p<0.05) transaminases (ALT 69.8±6.9 vs. 21.7±2.1U/l) and lower HDL (45.1 ±2.0 vs. 52.1 ±2.5 U/l) compared to controls. Fasting and 2 h plasma insulin concentrations were significantly (p<0.05) higher in NASH (31.0±3.4 μIU/dl and 213.7±24.7μIU/l) than medchemexpress controls (18.1 ±1.7 μIU/dl and 135.7±16.3 μIU/dl). Glucose AUC0-30 and Glucose AUC90-120 were not significantly different between NASH and control subjects. HOMA IR (7.61 ±0.8 vs. 4.37±0.4), Matsuda ISI (1.47±0.1 vs. 2.15±0.2), and QUICKI (0.293±0.003 vs. 0.313±0.004) were significantly

different (p<0.01) between NASH and controls. HIR measured by either method was not significantly different between NASH and controls. Insulin AUC90-120 was significantly higher (p<0.05) in patients with advanced NASH (defined using the ballooning and NAS scores). Conclusions. Compared to healthy controls, hyperinsulinemia and measures of peripheral IR rather than hepatic IR are increased in NASH. These data suggest that the skeletal muscle is a potential therapeutic target in NASH. Disclosures: The following people have nothing to disclose: Jaividhya Dasarathy, Ciaran E. Fealy, Carol A. Hawkins, Patricia T. Brandt, Arthur J. McCullough, John P. Kirwan, Srinivasan Dasarathy Background. Type 2 diabetes mellitus (T2DM) occurs in 30% of nonalcoholic fatty liver disease (NAFLD) and is the major independent risk factor for advanced fibrosis and nonalcoholic steatohepatitis (NASH- the severe type of NAFLD). However, there is no established effective therapy for NASH patients with T2DM. N-3 polyunsaturated fatty acids (PUFA) are dietary supplements that have been shown in animal and human studies to have a beneficial effect on many of the comorbidities associated with NASH.